Icon is a global contract research organization that provides outsourced clinical development services to pharmaceutical and biotechnology firms. Icon supports clients across late-stage clinical trials through the regulatory approval process and postmarket studies. Icon's services include clinical trial management, patient recruitment, data analytics, laboratory services, and regulatory consulting. With more than 40,000 employees operating in over 50 countries, the company partners with life sciences firms to run clinical trials and bring new drugs to market.
Last trade$194.43
Day change+$3.03 (+1.58%)
Day range$190.43 – $197.06
Volume310,737
Market cap$14.34B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$14.34B
Price / earnings
42.45×
Price / book
7.41×
Price / sales
4.88×
EV / sales
4.67×
EV / EBITDA
29.28×
Profitability
Earnings per share
$4.51
Return on assets
9.74%
Return on equity
17.46%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.18×
Current ratio
2.01×
Quick ratio
2.01×
Cash ratio
0.87×
Cash flow
Price / cash flow
26.69×
Price / free cash flow
29.34×
Free cash flow
$488.75M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for ICLR, quarterly periods
Line item
Q1 FY2021 Mar 31, 2021
Q4 FY2020 Dec 31, 2020
Q3 FY2020 Sep 30, 2020
Q2 FY2020 Jun 30, 2020
Q1 FY2020 Mar 31, 2020
Q4 FY2019 Dec 31, 2019
Q3 FY2019 Sep 30, 2019
Q2 FY2019 Jun 30, 2019
Revenue
$858.2M
$760.23M
$701.73M
$620.23M
$715.1M
$725.41M
$710.44M
$695.14M
Cost of revenue
$626.24M
$535.35M
$493.41M
$0
$505.29M
$508.19M
$499.79M
$490.66M
Gross profit
$231.95M
$224.88M
$208.32M
$620.23M
$209.81M
$217.22M
$210.65M
$204.48M
Selling, general and administrative
$98.54M
$87.88M
$83.12M
$83.5M
$87.2M
$86.18M
$85.45M
$83.2M
Research and development
—
—
—
—
—
—
—
—
Total operating expenses
$115.94M
$105.02M
$99.92M
$563.28M
$103.52M
$101.89M
$100.61M
$98.39M
Operating income
$116.01M
$119.86M
$108.4M
$56.95M
$106.29M
$115.33M
$110.04M
$106.09M
Interest expense
-$2.73M
-$3.38M
-$3.24M
-$3.22M
-$3.18M
-$3.33M
-$3.39M
-$3.2M
Income before taxes
$113.54M
$116.32M
$105.43M
$54.17M
$104.92M
$113.48M
$108.5M
$104.67M
Income taxes
$16.15M
$15.17M
$13.71M
$6.41M
$12.59M
$13.62M
$13.02M
$12.46M
Net income
$97.12M
$101.23M
$91.64M
$47.76M
$92.33M
$99.86M
$95.48M
$92.22M
Net income attributable to common shareholders
$97.12M
$101.23M
$91.64M
$47.76M
$87.17M
$95.2M
$93.58M
$91.86M
EBITDA
$133.42M
$119.86M
$125.2M
$90.9M
$122.61M
$115.33M
$125.2M
$121.28M
Basic earnings per share
$1.84
$1.92
$1.74
$0.91
$1.63
$1.77
$1.73
$1.70
Diluted earnings per share
$1.82
$1.90
$1.72
$0.90
$1.62
$1.76
$1.72
$1.69
Recent news
Company coverage with links to the original publishers.
Icon PLC reported Q3 2026 earnings of $2.66 per share, slightly beating consensus estimates of $2.64, with revenues of $2.02 billion. However, the company has underperformed the S&P 500 year-to-date, gaining only 0.9% versus the market's 12.1% gain. Despite the earnings beat, unfavorable estimate revisions ahead of the report resulted in a Zacks Rank #4 (Sell) rating, suggesting underperformance in the near term. The Medical Services industry ranks in the bottom 39% of Zacks industries.
Alignment Healthcare is expected to report a quarterly loss of $0.04 per share with revenues up 31.9% year-over-year for Q3 2026. The company has a negative Earnings ESP of -37.50% and a Zacks Rank of #4 (Sell), making it unlikely to beat consensus estimates. However, the company has beaten EPS estimates in all four of the last quarters.
The global rare disease CRO market is projected to grow from $2.07 billion in 2025 to $3.16 billion by 2030, with an 8.9% CAGR. Growth is driven by expanding gene and cell therapy pipelines, increasing orphan drug approvals, precision medicine adoption, and decentralized clinical trials. Key trends include AI integration, patient registries, and real-world evidence utilization.
CVS Health reported strong Q2 2026 results with adjusted EPS of $2.58 (up 42.5% YoY) and revenues of $106.10 billion (up 7.3%), beating consensus estimates. The company raised full-year 2026 guidance for earnings and revenues. However, estimates have trended downward over the past month with a -6.08% consensus shift, and the stock received a Zacks Rank #3 (Hold) rating with expectations for in-line returns.
The global eClinical Solutions market is projected to grow from USD 11.50 billion in 2025 to USD 42.55 billion by 2035, at a CAGR of 13.98%. Growth is driven by increased demand for efficient clinical trials, rising chronic disease prevalence, adoption of AI and cloud computing technologies, and decentralized trial models. Key players include Oracle, Veeva Systems, IQVIA, Medidata Solutions, and IBM Watson Health.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.